Emma Hajaj

Emma Hajaj

Auto-generated profile, based on publicly available information

Emma Hajaj

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MMMartino Maddalena
Martino Maddalena
GMGiuseppe Mallel
Giuseppe Mallel
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
MSMichal Shreberk-Shaked
Michal Shreberk-Shaked
OHOri Hassin
Ori Hassin
MOMoshe Oren
Moshe Oren
Significance: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, which is presently refractory to all available therapeutic strategies. PDAC tumors are characterized by a high degree of fibrosis, believed to be a major contributor to their therapy resistance. Mutations in the TP53 tumor suppressor gene are very frequent in PDAC. We now report that TP53 missense mutations, which lead to production of mutant p53 proteins, increase the extent of fibrosis and reduce the infiltration of cytotoxic CD8 + T cells. The inhibition of CD8 + T cell infiltration may augment the ability of PDAC tumors to evade the immune system. Hence, inhibition of the activities of mutant p53 may potentially sensitize PDAC tumors to anticancer treatments, including immunotherapy.

3 March 2020 in eLife
Verified
Journal Article
Open access
EHEmma Hajaj
Emma Hajaj
GEGalit Eisenberg
Galit Eisenberg
SKShiri Klein
Shiri Klein
SFShoshana Frankenburg
Shoshana Frankenburg
SMSharon Merims
Sharon Merims
MLMichal Lotem
Michal Lotem
SLAMF6 is a homotypic receptor of the Ig-superfamily whose exact role in immune modulation has remained elusive. Its constitutive expression on resting and activated T cells precludes it from being abona fideexhaustion marker. By breeding Pmel-1 mice with SLAMF6 -/- mice, we generated donors for T cells lacking SLAMF6 and expressing a transgenic TCR for gp100-melanoma antigen. Activated Pmel-1xSLAMF6 -/- CD8+ T cells displayed improved polyfunctionality and strong tumor cytolysis. T-bet was the dominant transcription factor in Pmel-1 x SLAMF6 -/- cells, and upon activation, they acquired an effector-memory phenotype. Adoptive transfer of Pmel-1 x SLAMF6 -/- T cells to melanoma-bearing mice resulted in lasting tumor regression in contrast to temporary responses achieved with Pmel-1 T cells. LAG-3 expression was elevated in the SLAMF6 -/- cells, and the addition of the LAG-3-blocking antibody to the adoptive transfer protocol improved the SLAMF6 -/- T cells and expedited the antitumor response even further. The results from this study support the notion that SLAMF6 is an inhibitory immune receptor whose absence enables powerful CD8+ T cells to eradicate tumors.

10 June 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
LLLisha Qiu Jin Lim
Lisha Qiu Jin Lim
LALital Adler
Lital Adler
EHEmma Hajaj
Emma Hajaj
LSLeandro R. Soria
Leandro R. Soria
RPRotem Ben-Tov Perry
Rotem Ben-Tov Perry
AEAyelet Erez
Ayelet Erez
Downregulation of the urea cycle enzyme argininosuccinate synthase (ASS1) in multiple tumors is associated with a poor prognosis partly because of the metabolic diversion of cytosolic aspartate for pyrimidine synthesis, supporting proliferation and mutagenesis owing to nucleotide imbalance. Here, we find that prolonged loss of ASS1 promotes DNA damage in colon cancer cells and fibroblasts from subjects with citrullinemia type I. Following acute induction of DNA damage with doxorubicin, ASS1 expression is elevated in the cytosol and the nucleus with at least a partial dependency on p53; ASS1 metabolically restrains cell cycle progression in the cytosol by restricting nucleotide synthesis. In the nucleus, ASS1 and ASL generate fumarate for the succination of SMARCC1, destabilizing the chromatin-remodeling complex SMARCC1–SNF5 to decrease gene transcription, specifically in a subset of the p53-regulated cell cycle genes. Thus, following DNA damage, ASS1 is part of the p53 network that pauses cell cycle progression, enabling genome maintenance and survival. Loss of ASS1 contributes to DNA damage and promotes cell cycle progression, likely contributing to cancer mutagenesis and, hence, adaptability potential.

27 March 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Multiple studies have identified metabolic changes within the tumor and its microenvironment during carcinogenesis. Yet, the mechanisms by which tumors affect the host metabolism are unclear. We find that systemic inflammation induced by cancer leads to liver infiltration of myeloid cells at early extrahepatic carcinogenesis. The infiltrating immune cells via IL6–pSTAT3 immune–hepatocyte cross-talk cause the depletion of a master metabolic regulator, HNF4α, consequently leading to systemic metabolic changes that promote breast and pancreatic cancer proliferation and a worse outcome. Preserving HNF4α levels maintains liver metabolism and restricts carcinogenesis. Standard liver biochemical tests can identify early metabolic changes and predict patients’ outcomes and weight loss. Thus, the tumor induces early metabolic changes in its macroenvironment with diagnostic and potentially therapeutic implications for the host. Significance: Cancer growth requires a permanent nutrient supply starting from early disease stages. We find that the tumor extends its effect to the host's liver to obtain nutrients and rewires the systemic and tissue-specific metabolism early during carcinogenesis. Preserving liver metabolism restricts tumor growth and improves cancer outcomes. This article is highlighted in the In This Issue feature, p. 1501

4 July 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
LLLisha Qiu Jin Lim
Lisha Qiu Jin Lim
LALital Adler
Lital Adler
EHEmma Hajaj
Emma Hajaj
LSLeandro R. Soria
Leandro R. Soria
RPRotem Ben-Tov Perry
Rotem Ben-Tov Perry
AEAyelet Erez
Ayelet Erez

14 July 2026 in Cancer Research
Verified
Journal Article
Open access
YAYarden Ariav
Yarden Ariav
SHSamah Hayek Hayek
Samah Hayek Hayek
TCThomas Cantore
Thomas Cantore
NSNeel Sanghvi
Neel Sanghvi
LALital N. Adler
Lital N. Adler
AEAyelet Erez
Ayelet Erez
Noncanonical metabolic functions of signaling molecules contribute to cancer plasticity and metastatic progression. In this study, we demonstrated that phosphodiesterase type 5A (PDE5A) inhibitors, including sildenafil (Sild; Viagra), induced lysosomal cholesterol accumulation across multiple mouse and human cancer models, reducing cholesterol bioavailability and impairing cancer cell migration and metastasis. Cancer cells exhibited heightened sensitivity due to reduced lysosomal gene expression, rendering them particularly vulnerable to disrupted cholesterol trafficking. Mechanistically, elevated guanosine 3′,5′-cyclic monophosphate (cGMP) bound the lysosomal cholesterol transporter NPC1, impairing cholesterol export and phenocopying Niemann–Pick type C pathology. The resulting cholesterol depletion disrupted membrane lipid rafts and mitochondrial bioenergetics, thereby limiting metastatic capacity and triggering compensatory sterol regulatory element–binding protein 2 (SREBP2) activation with increased cholesterol synthesis. Combining Sild with statins yields additive antimetastatic effects by concurrently blocking lysosomal cholesterol export and cholesterol biosynthesis. Consistently, analysis of digital health records demonstrated significantly improved survival among Sild users, with a dose-dependent additive benefit observed when combined with statins. Together, these findings identify increasing cGMP levels through PDE5A inhibition as a potential strategy to restrict metastasis and offer a potential mechanistic basis for the beneficial effects of Sild. Significance: PDE5A inhibition is linked to lysosomal cholesterol trafficking and reduced metastasis via cGMP-mediated disruption of NPC1 export, providing insights into how non-oncologic drugs and host–tumor metabolism influence progression and outcomes.